ALXO News and Press, ALX Oncology Holdings Inc. From 12/08/23

ALX Oncology Holdings Inc. (NASDAQ: ALXO) is one of today's top gainers. The company's shares have moved 2.92% on the day to $6.88. ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ...

2023-12-08 12:45:17 ET Gainers: Intensity Therapeutics ( INTS ) +100% . MBIA ( MBI ) +74% . Conduit Pharmaceuticals ( CDT ) +47% . EF Hutton Acquisition Corp I ( EFHT ) +44% . Alx Oncology Holdings ( ALXO ) +35% . View ( VI...

2023-12-08 12:14:56 ET DENVER, Colo., Dec. 8, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; MBIA Inc (NYSE: MBI), Intensity Therapeutics Inc (NASDAQ: INTS), MicroAlgo Inc (NASDAQ: MLGO), ALX Onco...

2023-12-08 10:53:50 ET More on ALX Oncology ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept ALX Oncology Holdings: Gilead News Creates A New Risk ALX Oncology GAAP EPS of -$1.24 misses by $0.37 ALX Oncology stock rockets 27% after bein...

2023-12-08 10:06:29 ET DENVER, Colo., Dec. 8, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; MBIA Inc (NYSE: MBI), Intensity Therapeutics Inc (NASDAQ: INTS), Hello Group Inc (NASDAQ: MOMO), MicroAlgo Inc...

2023-12-08 10:00:17 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Bluebird bio, ...

2023-11-21 04:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

ALX Oncology Holdings Inc. (ALXO) is expected to report $-0.86 for Q3 2023

2023-11-14 01:51:28 ET More on ALX Oncology ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept ALX Oncology Holdings: Gilead News Creates A New Risk ALX Oncology stock rockets 27% after being halted for volatility ALX Oncology announces p...

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results ...